Cancer Immunotherapy Market by Cancer Type (Blood Cancers, Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, Prostate Cancer, Others), Therapy Type (Cancer Vaccines, Immune Checkpoint Inhibitors – CTLA-4, PD-1/PD-L1, Immune System Modulators, Monoclonal Antibodies, Others), End Users (Ambulatory Surgical Centers, Cancer Research Centers, Clinics, Hospitals) and Forecast 2017-2021

Cancer Immunotherapy Market by Cancer Type (Blood Cancers, Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, Prostate Cancer, Others), Therapy Type (Cancer Vaccines, Immune Checkpoint Inhibitors – CTLA-4, PD-1/PD-L1, Immune System Modulators, Monoclonal Antibodies, Others), End Users (Ambulatory Surgical Centers, Cancer Research Centers, Clinics, Hospitals) and Forecast 2017-2021

Cancer immunotherapy is the use of the immune system to treat cancer. It uses substances either made by the body or in a laboratory to improve or restore immune system function. There are several types of cancer immunotherapies, including monoclonal antibodies, non-specific immunotherapies, oncolytic virus therapy, T-cell therapy, and cancer vaccines. FDA-approved antibodies include Alemtuzumab (Campeth-1H), Atezolizumab, Ipilimumab (Yervoy), Nivolumab, Ofatumumab, Pembrolizumab, Rituximab, etc. Besides monoclonal antibodies can be used as an immunotherapy, the PD-1/PD-L1 and CTLA-4 immune checkpoints pathways are critical to the immune system’s ability to control cancer growth. Ipilimumab (Yervoy), Nivolumab (Opdivo), and Pembrolizumab (Keytruda) are examples of immune checkpoint inhibitors. Like monoclonal antibodies, non-specific immunotherapies or cytokine therapy such as interferons – interferon alpha (Roferon-A [2a], Intron A [2b], Alferon [2a]) and interleukins – interleukin-2, IL-2, or aldesleukin (Proleukin) also help the immune system destroy cancer cells. HPV vaccine and Hepatitis B vaccine are the two cancer prevention vaccines approved by the U.S. FDA.

The global cancer immunotherapy market segmentation is based on cancer type (blood cancers, breast cancer, colorectal cancer, lung cancer, melanoma, prostate cancer, others), therapy type (cancer vaccines, immune checkpoint inhibitors – CTLA-4, PD-1/PD-L1, immune system modulators, monoclonal antibodies, others), end users (ambulatory surgical centers, cancer research centers, clinics, hospitals).

The global cancer immunotherapy market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global cancer immunotherapy market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global cancer immunotherapy market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

Major players operating in the global cancer immunotherapy market and profiled in this report include Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Janssen Biotech, Inc., Merck & Co., Novartis AG, Pfizer, Inc., Sanofi, Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceuticals.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Cancer Immunotherapy Market

1. Cancer Type
1.1. Blood Cancers
1.2. Breast Cancer
1.3. Colorectal Cancer
1.4. Lung Cancer
1.5. Melanoma
1.6. Prostate Cancer
1.7. Others

2. Therapy Type
2.1. Cancer Vaccines
2.2. Immune Checkpoint Inhibitors
2.2.1. CTLA-4
2.2.2. PD-1/PD-L1
2.3. Immune System Modulators
2.4. Monoclonal Antibodies
2.5. Others

3. End Users
3.1. Ambulatory Surgical Centers
3.2. Cancer Research Centers
3.3. Clinics
3.4. Hospitals

4. Geography (Region, Country)
4.1. North America (U.S., Canada)
4.2. Latin America (Brazil, Mexico, Rest of LA)
4.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
4.4. Asia Pacific (Japan, China, India, Rest of APAC)
4.5. Rest of the World

5. Company Profiles
5.1. Amgen, Inc.
5.2. AstraZeneca Plc
5.3. Bristol-Myers Squibb Company
5.4. Eli Lilly and Company
5.5. F. Hoffmann-La Roche Ltd.
5.6. GlaxoSmithKline Plc.
5.7. Janssen Biotech, Inc.
5.8. Merck & Co.
5.9. Novartis AG
5.10. Pfizer, Inc.
5.11. Sanofi
5.12. Spectrum Pharmaceuticals, Inc.
5.13. Takeda Pharmaceuticals

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*